Author

J. Taunton

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Cancer Biology· 2 Biophysics· 1 Cell Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 5 Approach:experimental assay· 5 Organism:human· 4 Assay:proteomics· 4 Organism:mouse· 3 Research Focus:cell signaling & trafficking· 2 Approach:deep learning· 2 Research Focus:protein folding & dynamics· 2

Frequent Co-Authors

A. P. Wiita· 2 shared J. D. Carelli· 2 shared K. Oltion· 2 shared M. Holm· 2 shared M. Kampmann· 2 shared A. A. Q. Al-Khdhairawi· 1 shared A. B. Abarientos· 1 shared A. Brown· 1 shared

Activity by Year

2017-2022 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. P. Wiita

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Didemnin B and ternatin-4 inhibit conformational changes in eEF1A required for aminoacyl-tRNA accommodation into mammalian ribosomes

M. F. Juette, J. D. Carelli, E. J. Rundlet, A. Brown, S. Shao, A. Ferguson, M. R. Wasserman, M. Holm, J. Taunton, S. C. Blanchard

This study shows how didemnin B and ternatin-4 inhibit translation by trapping eEF1A in a GTPase-activated conformation using single-molecule imaging and cryo-EM.

bioRxiv · Aug 1, 2022 · PreprintBiochemistry

Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors

E. A. Fink, C. Bardine, S. Gahbauer, I. Singh, K. White, S. Gu, X. Wan, B. Ary, I. Glenn, J. O'Connell, H. O'Donnell, P. Fajtova, J. Lyu, S. Vigneron, N. J. Young, , C. S. Craik

The paper identifies novel non-covalent and covalent inhibitors of SARS-CoV-2 main protease through virtual docking and experimental validation.

bioRxiv · Jul 5, 2022Biophysics

Signal peptide mimicry primes Sec61 for client-selective inhibition

S. Rehan, D. Tranter, P. P. Sharp, E. Lowe, J. Anderl, T. Muchamuel, V. Abrishami, S. Kuivanen, N. Wenzell, A. Jennings, C. Kalyanaraman, G. B. Craven, T. Strandin, M. Javanainen, O. Vapalahti, , V. Paavilainen

This study describes KZR-8445, a cyclic depsipeptide that selectively inhibits Sec61-mediated protein biogenesis by mimicking signal peptides, showing efficacy in a rheumatoid arthritis model.

bioRxiv · Jul 3, 2022Biochemistry

An E3 ligase network engages GCN1 to promote elongation factor-1α degradation on stalled ribosomes

K. Oltion, J. D. Carelli, T. Yang, S. K. See, H.-Y. Wang, M. Kampmann, J. Taunton

The paper identifies an E3 ligase network that promotes eEF1A degradation on stalled ribosomes through interaction with GCN1.

bioRxiv · Mar 21, 2022 · PreprintCell Biology

Synthesis and single-molecule imaging reveal stereospecific enhancement of binding kinetics by the antitumor eEF1A antagonist SR-A3

H. Wang, H. Yang, M. Holm, K. Oltion, H. Tom, A. A. Q. Al-Khdhairawi, J.-F. F. Weber, S. Blanchard, D. Ruggero, J. Taunton

This study synthesizes and characterizes SR-A3, a stereoisomer of a natural product, showing enhanced binding kinetics and therapeutic efficacy in a mouse lymphoma model.

bioRxiv · Oct 6, 2020Pharmacology & Toxicology

CRISPR-based screens uncover determinants of immunotherapy response in Multiple Myeloma

P. Ramkumar, A. B. Abarientos, R. Tian, M. Seyler, J. T. Leong, M. Chen, P. Choudhry, T. Hechler, N. Shah, S. W. Wong, T. G. Martin, J. L. Wolf, K. T. Roybal, A. Pahl, J. Taunton, , M. Kampmann

This study uses CRISPR screens to identify mechanisms increasing BCMA expression and enhancing anti-myeloma efficacy of BCMA-targeted therapies in multiple myeloma.

bioRxiv · Apr 14, 2020Cancer Biology

Repurposing Tofacitinib As An Anti-Myeloma Therapeutic To Reverse Growth-Promoting Effects Of The Bone Marrow Microenvironment

C. Lam, M. Murnane, H. Liu, G. A. Smith, S. Wong, J. Taunton, J. O. Liu, C. S. Mitsiades, B. C. Hann, B. T. Aftab, A. P. Wiita

This paper validates tofacitinib as an effective anti-myeloma therapy by reversing bone marrow microenvironment-driven growth signals in vitro and in vivo.

bioRxiv · May 28, 2017Cancer Biology